ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1306

Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis

George Karpouzas1, Sarah Ormseth2, Piet Van Riel3, Elena Myasoedova4, Miguel A Gonzalez-Gay5, Alfonso Corrales6, Solbritt Rantapaa-Dahlqvist7, Petros Sfikakis8, Patrick Dessein9, Linda Tsang9, Carol Hitchon10, Hani El Gabalawi11, Virginia Pascual Ramos12, Irazú Contreras Yañez13, Iris Colunga14, Dionicio A. Galarza-Delgado14, José Ramón Azpiri-López14, Silvia Rolefstad15, Anne Grete Semb16, Durga P Misra17, George Kitas18 and Ellen-Margrethe Hauge19, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Torrance, CA, 3Radboud University Medical Center, Drunen, Netherlands, 4Mayo Clinic, Rochester, MN, 5IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 6Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 7Umeå University, Umeå, Umea, Sweden, 8National Kapodistrian University of Athens Medical School, Athens, Greece, 9University of Witwatersrand, Johannesburg, South Africa, 10University of Manitoba, Manitoba, MB, Canada, 11University of Manitoba, Winnipeg, MB, Canada, 12Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 13Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 14Hospital Universitario UANL, Monterrey, Mexico, 15Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, 16Diakonhjemmet Hospital, Oslo, Norway, 17Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 18The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, 19Aarhus University Hospital, Aarhus, Denmark

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Baseline and cumulative inflammation have both been associated with increased cardiovascular event (CVE) risk in patients with rheumatoid arthritis (RA). Statin therapy reduced systemic inflammation, attenuated coronary atherosclerosis progression and promoted plaque calcification and stabilization1 both in general as well as RA patients. We here explored whether baseline statin use influenced the impact of baseline C-reactive protein (CRP) on long-term cardiovascular risk in patients with RA.

Methods: We evaluated 4,357 patients without known cardiovascular disease upon registration to An International Cardiovascular Consortium for people with RA (ATACC-RA) and who were followed prospectively. The primary outcome was ischemic CVE defined as the composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, stable angina pectoris, transient ischemic attack, and peripheral arterial disease with or without revascularization. Missing data were imputed using multiple imputation with 10 repetitions. Multivariable Cox models stratified by center evaluated the effect of natural logarithm of CRP, statin use and their interaction on CVE risk after adjusting for age, gender, hypertension, diabetes, family history, smoking, age at RA diagnosis, and total cholesterol to high-density lipoprotein (TC/HDL)ratio. A sensitivity analysis was performed using inverse probability of treatment weights to balance differences between statin treated and untreated patients.

Results: At baseline 462 patients were treated with statins whereas 3,895 were not. Statin therapy inversely associated with low density lipoprotein cholesterol (p< 0.001), TC/HDL ratio (p< 0.001) and CRP(ln) (p=0.048). Over 26,356 patient years (PY) of follow-up, 361 total ischemic CVE were recorded, 321 over 24,235 PY in statin nonusers and 40 over 2,121 PY in statin users. Incidence of any ischemic CVE was 13.3 (95% CI 11.9-14.8)/1000PY among statin nonusers and 18.9 (95% CI 13.8-25.7)/1000PY in statin users (incidence rate difference 5.62 [95% CI -0.41 to 11.64]). In the entire cohort, baseline CRP(ln) was not associated with ischemic CVE risk, [adjusted hazards ratio- aHR 1.07 (95% CI 0.98-1.17), p=0.138]. However, higher CRP(ln) associated with greater risk of the composite outcome exclusively in statin nonusers [aHR 1.10 (95% CI 1.01-1.21), p=0.036] but not in statin users (p-interaction=0.032, Figures 1 and 2). While CRP(ln) was not different between statin groups after inverse probability weighting adjustment (p=0.333), the sensitivity analysis yielded similar results: higher CRP(ln) associated with greater ischemic CVE risk in statin nonusers [aHR 1.11 (95% CI 1.01-1.22), p=0.030] but not among statin users (p-interaction=0.046).

Conclusion: Higher inflammation at baseline associated with greater risk of any ischemic CVE among statin nonusers but not in users. This points to the potential of statin-specific effects directly on atherosclerotic plaque—such as lower progression and stabilization1—above and beyond effects on cholesterol metabolism and systemic inflammation.

Reference: Karpouzas GA et al. Rheumatology (Oxford) 2022;61(5):1857-1866

Supporting image 1

Supporting image 2


Disclosures: G. Karpouzas: Janssen, 1, Pfizer, 5, Scipher, 1; S. Ormseth: None; P. Van Riel: None; E. Myasoedova: None; M. Gonzalez-Gay: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Pfizer, 5, 6; A. Corrales: None; S. Rantapaa-Dahlqvist: None; P. Sfikakis: AbbVie/Abbott, 2, 5, Amgen, 2, 5, Boehringer-Ingelheim, 2, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5; P. Dessein: None; L. Tsang: None; C. Hitchon: None; H. El Gabalawi: None; V. Pascual Ramos: None; I. Contreras Yañez: None; I. Colunga: None; D. Galarza-Delgado: None; J. Azpiri-López: None; S. Rolefstad: None; A. Semb: None; D. Misra: None; G. Kitas: None; E. Hauge: None.

To cite this abstract in AMA style:

Karpouzas G, Ormseth S, Van Riel P, Myasoedova E, Gonzalez-Gay M, Corrales A, Rantapaa-Dahlqvist S, Sfikakis P, Dessein P, Tsang L, Hitchon C, El Gabalawi H, Pascual Ramos V, Contreras Yañez I, Colunga I, Galarza-Delgado D, Azpiri-López J, Rolefstad S, Semb A, Misra D, Kitas G, Hauge E. Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/statin-use-attenuates-the-impact-of-systemic-inflammation-on-ischemic-cardiovascular-risk-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/statin-use-attenuates-the-impact-of-systemic-inflammation-on-ischemic-cardiovascular-risk-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology